In the BioHarmony Drug Report Database

"Preview" Icon

Opicapone

Ongentys (opicapone) is a small molecule pharmaceutical. Opicapone was first approved as Ongentys on 2016-06-24. It is used to treat parkinson disease in the USA. It has been approved in Europe to treat parkinson disease. The pharmaceutical is active against catechol O-methyltransferase. Ongentys’s patents are valid until 2035-05-27 (FDA).

 

Trade Name

 

Ongentys
 

Common Name

 

opicapone
 

ChEMBL ID

 

CHEMBL1089318
 

Indication

 

parkinson disease
 

Drug Class

 

Catechol-O-methyltransferase (COMT) inhibitors

Image (chem structure or protein)

Opicapone structure rendering